Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 501–600 of 1,029
The effects of APOE genotype on age at onset and progression of neurodegenerative diseases
Chapman, J., Korczyn, A. D., Karussis, D. M., & Michaelson, D. M. (2001) · Neurology · doi:10.1212/wnl.57.8.1482 · Cited by 67
Malignancy of recurrent, early‐onset major depression: A family study
Zubenko, G. S., Zubenko, W. N., Spiker, D. G., Giles, D. E., & Kaplan, B. B. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1554 · Cited by 68
Familial Dementia With Lewy Bodies: A Clinical and Neuropathological Study of 2 Families
Tsuang, D. W., Dalan, A. M., Eugenio, C. J., Poorkaj, P., Limprasert, P., La Spada, A. R., Steinbart, E. J., Bird, T. D., & Leverenz, J. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1622 · Cited by 67
Müller, W., Meske, V., Berlin, K., Scharnagl, H., März, W., & Ohm, T. G. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00190.x · Cited by 67
“Mean increases of [Ca]i evoked by 20 nmol/l apoE isoforms E2, E3, E4, 5 mM bA4-amyloid (1-43), combinations of apoE and bA4 and, for control, a protein with the reversed sequence of amino acids 1-40 of bA4 (rev bA4) in the presence of CNQX (10 mM), a blocker of fast glutamatergic excitation, in primary hippocampal cul…”
BackgroundProtective effect of apoE ∈2 in Alzheimer's disease
Benjamin, R., Leake, A., McArthur, F. K., Ince, P. G., Candy, J. M., Edwardson, J. A., Morris, C. M., & Bjertness, E. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91804-x · Cited by 79
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. H. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 66
Common human genetic variants of APOE impact murine COVID-19 mortality
Ostendorf, B. N., Patel, M. A., Bilanovic, J., Hoffmann, H.-H., Carrasco, S. E., Rice, C. M., & Tavazoie, S. F. (2022) · Nature · doi:10.1038/s41586-022-05344-2 · Cited by 61
Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J., Cho, M., & Hampel, H. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 66
“By contrast, APOE ε2 remains the strongest genetic protective factor against sporadic AD 7,8 , with very few APOE ε2 / ε2 individuals developing AD up to the age of 90 years 14,18 .”
Gene-Environment Interaction in Alzheimer’s Disease:A Potential Role for Cholesterol
Chandra, V., & Pandav, R. (1998) · Neuroepidemiology · doi:10.1159/000026175 · Cited by 66
Competition of Aβ amyloid peptide and apolipoprotein E for receptor-mediated endocytosis
Winkler, K., Scharnagl, H., Tisljar, U., Hoschützky, H., Friedrich, I., Hoffmann, M. M., Hüttinger, M., Wieland, H., & März, W. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32449-4 · Cited by 66
Marutle, A., Warpman, U., Bogdanovic, N., Lannfelt, L., & Nordberg, A. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0721161.x · Cited by 66
Misserise mutation of S182 gene in Italian families with early-onset Alzheimer's disease
Sorbi, S., Nacmias, B., Forleo, P., Piacentini, S., Sherrington, R. P., Rogaev, E. I., & Amaducci, L. A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92809-x · Cited by 66
Rajabli, F., Beecham, G. W., Hendrie, H. C., Baiyewu, O., Ogunniyi, A., Gao, S., Kushch, N. A., Lipkin-Vasquez, M., Hamilton-Nelson, K. L., Young, J. I., et al. (2022) · PLOS Genetics · doi:10.1371/journal.pgen.1009977 · Cited by 65
“32) is the strongest genetic risk factor for late-onset Alzheimer disease (AD) and is associated with an earlier age-of-onset [1,2].”
BackgroundSelf-citationBarabash, A., Marcos, A., Ancín, I., Vázquez-Álvarez, B., de Ugarte, C., Gil, P., Fernández, C., Encinas, M., López-Ibor, J. J., & Cabranes, J. A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.003 · Cited by 73
Apolipoprotein E ε4 Allele Frequency and Age at Onset of Alzheimer’s Disease
Davidson, Y., Gibbons, L., Pritchard, A., Hardicre, J., Wren, J., Stopford, C., Julien, C., Thompson, J., Payton, A., Pickering-Brown, S. M., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000097038 · Cited by 64
“Genetic variations represent major risk factors for Alzheimer’s disease (AD). Familial, autosomal dominant, early onset AD (EOAD) is associated with mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes. However, for late onset AD (LOAD; i.e. those with age of onset, AAO, after 65 yea…”
BackgroundApolipoprotein E and central nervous system disorders: Reviews of clinical findings
Takeda, M., Martínez, R., Kudo, T., Tanaka, T., Okochi, M., Tagami, S., Morihara, T., Hashimoto, R., & Cacabelos, R. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02148.x · Cited by 65
The Interaction of Amyloid-β with ApoE
Carter, D. B. (2005) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/0-387-23226-5_13 · Cited by 80
Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M. J. T., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-018-0273-5 · Cited by 65
Burgess, B. L., Parkinson, P. F., Racke, M. M., Hirsch-Reinshagen, V., Fan, J., Wong, C., Stukas, S., Theroux, L., Chan, J. Y., Donkin, J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700481-jlr200 · Cited by 65
Corder, E. H., Jelic, V., Basun, H., Lannfelt, L., Valind, S., Winblad, B., & Nordberg, A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550150035013 · Cited by 65
Self-citationCao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Ramsay, R., & Fahy, T. (1995) · BMJ · doi:10.1136/bmj.311.6998.167 · Cited by 64
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Self-citationHui, L., Chen, X., & Geiger, J. D. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.039 · Cited by 58
“In contrast, people bearing the ApoE2 allele, a protective factor against sporadic AD (Corder et al., 1996, 1994; Schachter et al., 1994), have lower levels of plasma cholesterol (Scuteri et al., 2001; Wisdom et al., 2011).”
Perspectives on the Amyloid-β Cascade Hypothesis
Lee, H., Casadesús, G., Zhu, X., Joseph, J. A., Perry, G. L., & Smith, M. A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6205 · Cited by 72
“Interestingly, the ApoE2 is capable of inhibiting the formation of fibrils and is protective against the development of AD [20].”
Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran
Vaisi‐Raygani, A., Zahrai, M., Raygani, A. V., Doosti, M., Javadi, E., رضایی, م., & Pourmotabbed, T. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.073 · Cited by 65
HYMAN, B. T., GOMEZ‐ISLA, T., REBECK, G. W., BRIGGS, M., CHUNG, H., WEST, H. L., GREENBERG, S., MUI, S., NICHOLS, S., WALLACE, R., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32592.x · Cited by 64
Chasman, D. I., Kozłowski, P., Zee, R. Y. L., Kwiatkowski, D. J., & Ridker, P. M. (2006) · Genes and Immunity · doi:10.1038/sj.gene.6364289 · Cited by 70
Apolipoprotein E genotypes and cognitive functions in healthy elderly persons
Staehelin, H. B., Perrig-Chiello, P., Mitrache, C., Miserez, A. R., & Perrig, W. J. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00723.x · Cited by 64
van Gool, W. A., Evenhuis, H. M., van Duijn, C. M., & Behalf of the Dutch Study Group on Down's Syndrome and Ageing (1995) · Annals of Neurology · doi:10.1002/ana.410380215 · Cited by 64
Pettigrew, C. A., Soldan, A., Li, S., Lu, Y., Wang, M., Selnes, O. A., Moghekar, A., O’Brien, R., Albert, M., & Research Team the BIOCARD (2013) · Cognitive Neuroscience · doi:10.1080/17588928.2013.831820 · Cited by 63
“In contrast to some previous findings (e.g., Corder et al., 1994), we did not find an independent, protective effect of the ε2 allele on time to onset of clinical symptoms.”
BackgroundResultInfluence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study
Li, B., Shi, J., Gutman, B. A., Baxter, L. C., Thompson, P. M., Caselli, R. J., Wang, Y., & Initiative, A. D. N. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152901 · Cited by 63
Konishi, K., Bhat, V., Banner, H., Poirier, J., Joober, R., & Bohbot, V. D. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00349 · Cited by 74
Kay, A. D., Petzold, A., Kerr, M., Keir, G., Thompson, E., & Nicoll, J. A. R. (2003) · Journal of Neurotrauma · doi:10.1089/089771503770195795 · Cited by 63
“…gene ( « 3/3, « 3/4, « 4/4, « 2/3, « 2/4, « 2/2) influences risk for the development of the sporadic form of AD; possession of the APOE « 4 allele confers increased risk, whereas in contrast the more frequent APOE « 3 or rare APOE « 2 alleles reduce risk (Corder et al., 1994; Farrer et al., 1997).”
Physical activity, inflammation, and volume of the aging brain
Braskie, M. N., Boyle, C. P., Rajagopalan, P., Gutman, B. A., Toga, A. W., Raji, C. A., Tracy, R. P., Kuller, L. H., Becker, J. T., Lopez, O. L., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.005 · Cited by 63
“…cite this article in press as: Braskie MN et al. Physical activity, inflam dx.doi.org/10.1016/j.neuroscience.2014.05.005 APOE genotype Apolipoprotein E allele e4 (APOE4) is a known genetic risk factor for late onset AD (Corder et al., 1993), while allele e 2 reduces AD risk (Corder et al., 1994).”
InfluentialLeduc, V, De Beaumont, L., Théroux, L., Dea, D., Aisen, P., Petersen, R. C., Initiative, T. A. D. N., Dufour, R., & Poirier, J. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.81 · Cited by 63
“As reported previously in several independent studies (16, 17), a very similar protective effect was observed with the APOE2 allele [Wilcoxon Survival test: X2 1, 289= 5.”
ResultAPOE Genotype and Cognitive Change in Young, Middle-Aged, and Older Adults Living in the Community
Bunce, D., Bielak, A. A. M., Anstey, K. J., Cherbuin, N., Batterham, P. J., & Easteal, S. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt103 · Cited by 63
“In old age, the protective effect of the ɛ2 allele is widely recognized (eg, reference [2]).”
BackgroundCambon, K., Davies, H. A., & Stewart, M. G. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00065-8 · Cited by 63
Psychopathology in the Postgenomic Era
Plomin, R., & McGuffin, P. (2003) · Annual Review of Psychology · doi:10.1146/annurev.psych.54.101601.145108 · Cited by 63
Genetic Testing for Alzheimer Disease: Practical and Ethical Issues
Roses, A. D. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550220036011 · Cited by 67
Self-citationAPOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
Quiroz, Y. T., Aguillon, D., Aguirre-Acevedo, D. C., Vasquez, D., Zuluaga, Y., Baena, A. Y., Madrigal, L., Hincapié, L., Sanchez, J. S., Langella, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308583 · Cited by 63
Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
Dai, J., Johnson, E. C. B., Dammer, E. B., Duong, D. M., Gearing, M., Lah, J. J., Levey, A. I., Wingo, T. S., & Seyfried, N. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00454 · Cited by 62
“Genetic analysis of late-onset AD has uncovered a number of single nucleotide polymorphisms (SNPs) that are associated with risk for the disease, but by far the strongest risk factor on a population level is genetic variation in the apolipoprotein E (APOE) gene (Strittmatter et al., 1993; Corder et al., 1994; Lambert…”
BackgroundShu, H., Shi, Y., Chen, G., Wang, Z., Liu, D., Yue, C., Ward, B. D., Li, W., Xu, Z., Chen, G., et al. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhu237 · Cited by 62
“The apolipoprotein E (APOE) gene serves as the established genetic factor that influences AD onset in an isoformdependent manner (ε4 > ε3 > ε2) (Corder et al. 1994; Seripa et al. 2009).”
BackgroundBlazer, D. G., Fillenbaum, G. G., & Burchett, B. M. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.12.m785 · Cited by 62
“E4 has been proposed as a susceptibility gene for late age onset of sporadic Alzheimer’s disease and subsequent cognitive decline (1,2).”
BackgroundRAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
“Those with the strongest protective effect include APOE ε2 and APP-A673T.(34,35) Thus, genes and pathways involved in increasing AD risk may also confer resilience to disease.”
Dancing in the Dark? The Status of Late-Onset Alzheimer's Disease Genetics
Bertram, L., & Tanzi, R. E. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:127 · Cited by 65
Hirsch-Reinshagen, V., & Wellington, C. L. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32813aeabf · Cited by 61
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Félician, O., & Sandson, T. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.1.19 · Cited by 70
THE GENETICIST'S APPROACH TO COMPLEX DISEASE
Ghosh, S., & Collins, F. S. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.333 · Cited by 77
Alzheimer’s Disease – The Past, the Present and the Future
Botchway, B. O. A., & Iyer, I. C. (2017) · Science Journal of Clinical Medicine · doi:10.11648/j.sjcm.20170601.11 · Cited by 63
“APOE 2,4, are at normal risk similar to the APOE 3,3 genotype [97].”
BackgroundWalters, S., Contreras, A. G., Eissman, J. M., Mukherjee, S., Lee, M. L., Choi, S.-E., Scollard, P., Trittschuh, E. H., Mez, J. B., Bush, W. S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2169 · Cited by 60
Self-citationZetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 60
A search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways
Logue, M. W., Schu, M., Vardarajan, B. N., Farrell, J., Lunetta, K. L., Jun, G., Baldwin, C. T., DeAngelis, M. M., & Farrer, L. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.007 · Cited by 60
“The ε4 allele confers increased risk of AD and the ε2 allele is protective (Corder et al., 1994; Corder et al., 1993; Farrer et al., 1997), effect directions opposite to those reported with AMD (McKay et al.”
Reas, E. T., Laughlin, G. A., Kritz‐Silverstein, D. C., Barrett-Connor, E. L., & McEvoy, L. K. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.89 · Cited by 67
Graham, D. I., Gentleman, S., Nicoll, J. A. R., Royston, M. C., McKenzie, J. E., Roberts, G. W., & Griffin, W. S. T. (1996) · Springer eBooks · doi:10.1007/978-3-7091-9465-2_17 · Cited by 70
Alzheimer's disease and apolipoprotein e‐4 allele in an amish population
Pericak‐Vance, M. A., Johnson, C. C., Rimmler, J. B., Saunders, A. M., Robinson, L. C., D'Hondr, E. G., Jackson, C. E., & Haines, J. L. (1996) · Annals of Neurology · doi:10.1002/ana.410390605 · Cited by 60
Self-citationApolipoprotein E and Alzheimer's Disease: A Review of Recent Studies
Higgins, G. A., Large, C. H., Rupniak, H. T., & Barnes, J. C. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00420-0 · Cited by 64
Harrington, C. R., & Colaco, C. A. L. S. (1994) · Nature · doi:10.1038/370247a0 · Cited by 66
Apolipoprotein E ε2 Allele and Risk of Stroke in the Older Population
Ferrucci, L., Guralnik, J. M., Pahor, M., Harris, T. B., Corti, M.-C., Hyman, B. T., Wallace, R. B., & Havlik, R. J. (1997) · Stroke · doi:10.1161/01.str.28.12.2410 · Cited by 66
Meier-Ruge, W., & Bertoni-Freddari, C. (1996) · Reviews in the Neurosciences · doi:10.1515/revneuro.1996.7.1.1 · Cited by 60
Complete Genomic Screen in Late-Onset Familial Alzheimer’s Disease
Pericak‐Vance, M. A., Bass, M. L., Yamaoka, L. H., Gaskell, P. C., Scott, W. K., Terwedow, H. A., Menold, M. M., Conneally, P. M., Small, G. W., Saunders, A. M., et al. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00037-2 · Cited by 58
Self-citationRajan, K. B., Barnes, L. L., Wilson, R. S., McAninch, E. A., Weuve, J., Sighoko, D., & Evans, D. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15059 · Cited by 59
The effects of APOE on brain activity do not simply reflect the risk of Alzheimer's disease
Trachtenberg, A. J., Filippini, N., Cheeseman, J., Duff, E. P., Neville, M. J., Ebmeier, K. P., Karpe, F., & Mackay, C. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.011 · Cited by 68
“All rights reserved. doi:10.1016/j.neurobiolaging.2010.11.011 develop the disease than 3 homozygotes (Corder et al., 1994; Myers et al., 1996).”
InfluentialLehmann, D. J., Williams, J. H., Mcbroom, J., & Smith, A. D. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00464-x · Cited by 61
Belbin, O., Dunn, J. L., Ling, Y., Morgan, L., Chappell, S., Beaumont, H., Warden, D., Smith, D. A., Kalsheker, N., & Morgan, K. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm171 · Cited by 59
“Interestingly, the APOE 12 allele is underrepresented in AD cases (7) and is associated with a delayed age at onset of AD (2,6) suggesting a protective effect (8).”
BackgroundApolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam study
Slooter, A. J. C., van Duijn, C. M., Bots, M. L., Ott, A., Breteler, M. M. B., Voecht, J. D., Wehnert, A., de Knijff, P., Havekes, L. M., Grobbee, D. E., et al. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_3 · Cited by 69
The Apolipoprotein E E4 Allele and Sex-Specific Risk of Alzheimer's Disease
Corder, E. H. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520290025013 · Cited by 58
Self-citationLate-onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD
Carrasquillo, M. M., Khan, Q. U. A., Murray, M. E., Krishnan, S., Aakre, J., Pankratz, V. S., Nguyen, T., Ma, L., Bisceglio, G., Petersen, R. C., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000335 · Cited by 57
Effect of APOE genotype and promoter polymorphism on risk of Alzheimer’s disease
Wang, J. C., Kwon, J. M., Shah, P., Morris, J. C., & Goate, A. (2000) · Neurology · doi:10.1212/wnl.55.11.1644 · Cited by 49
“Control (%) 34 (6) 444 (81) 70 (13) 548 2 (1) 22 (8) 184 (67) 8 (3) 54 (20) 4 (1) 274”
Apolipoprotein E in Alzheimer's disease risk and case detection: A case-control study
Kukull, W. A., Schellenberg, G. D., Bowen, J. D., McCormick, W. C., Yu, C., Teri, L. L., Thompson, J. D., O’Meara, E. S., & Larson, E. B. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00195-3 · Cited by 64
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 74
Arold, S., Sullivan, P., Bilousova, T., Teng, E., Miller, C. A., Poon, W. W., Vinters, H. V., Cornwell, L. B., Saing, T., Cole, G. M., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0892-1 · Cited by 57
“The human gene exists in three alleles, (E2, E3 and E4); while APOE4 confers risk for AD [9], APOE2 is protective [8].”
Small, G. W., Siddarth, P., Burggren, A. C., Kepe, V., Ercoli, L. M., Miller, K. J., Lavretsky, H., Thompson, P. M., Cole, G. M., Huang, S. C., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.516 · Cited by 57
“The APOE-4 allele increases risk and decreases the average age of dementia onset in a doserelated fashion (ie, AD risk is lowest for the 3/3 genotype, higher for the 3/4 genotype, and highest for the 4/4 genotype),(14) while APOE-2 lowers the risk.(15) Because APOE-4 accounts for only part of the genetic risk for AD,…”
Self-citationOlgiati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D., & Serretti, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/832379 · Cited by 57
“Another variant of the APOE gene, e2, has protective effects against the development of AD [20, 21].”
BackgroundApolipoprotein E, Statins, and Risk of Intracerebral Hemorrhage
Woo, D., Deka, R., Falcone, G. J., Flaherty, M. L., Haverbusch, M. A., Martini, S. R., Greenberg, S. M., Ayres, A. M., Sauerbeck, L. R., Kissela, B. M., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001304 · Cited by 62
ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation
Huang, D. Y., Weisgraber, K. H., Goedert, M., Saunders, A. M., Roses, A. D., & Strittmatter, W. J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11649-h · Cited by 66
Self-citationIncreased 3-nitrotyrosine in brains of Apo E-deficient mice
Matthews, R. T., & Beal, M. F. (1996) · Brain Research · doi:10.1016/0006-8993(95)01576-0 · Cited by 62
Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics
Cacabelos, R., Martínez, R., Fernández‐Novoa, L., Carril, J. C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., et al. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/518901 · Cited by 68
“In recent times, significant advances have propelled the introduction of pharmacogenomic approaches in drug development and also in clinical practice to optimize therapeutics [4–8].”
BackgroundClinical Genetics of Alzheimer’s Disease
Zou, Z., Liu, C., Che, C., & Huang, H. (2014) · BioMed Research International · doi:10.1155/2014/291862 · Cited by 71
“One copy of the ε4-allele of APOE increases AD risk by 4-fold and two copies increase the risk by 12-fold; by contrast, the ε2-allele of APOE is protective against AD [79].”
Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models
Cenini, G., Hebisch, M., Iefremova, V., Flitsch, L. J., Breitkreuz, Y., Tanzi, R. E., Kim, D. Y., Peitz, M., & Brüstle, O. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103568 · Cited by 56
Apolipoprotein E and brain injury: implications for children
Blackman, J. A., Worley, G., & Strittmatter, W. J. (2005) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162205000113 · Cited by 66
Self-citationA subset of senile dementia with high incidence of the apolipoprotein E ϵ2 allele
Ikeda, K., Akiyama, H., Arai, T., Sahara, N., Mori, H., Usami, M., Sakata, M., Mizutani, T., Wakabayashi, K., & Takahashi, H. (1997) · Annals of Neurology · doi:10.1002/ana.410410522 · Cited by 55
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 62
Cacciapuoti, F. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0856-x · Cited by 57
Risk and protective factors for sporadic Alzheimer's disease.
Stožická, Z., Žilka, N., & Novák, M. (2007) · PubMed · Cited by 73
Iwata, H., Uga, Y., Yoshioka, Y., Ebana, K., & Hayashi, T. (2007) · Theoretical and Applied Genetics · doi:10.1007/s00122-007-0529-x · Cited by 65
“Association mapping has been used to dissect the genetic basis of human disease (e.g. Kerem et al. 1989; Corder et al. 1994), and has recently been extended to plants (Thornsberry et al.”
MethodVERBEEK, M. M., VAN NOSTRAND, W. E., OTTE‐HÖLLER, I., WESSELING, P., & DE WAAL, R. M. W. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06368.x · Cited by 55
The genetics of Alzheimer’s disease
Schellenberg, G. D., D’Souza, I., & Poorkaj, P. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0061-z · Cited by 56
Apolipoprotein E Genotype and Deposits of Aβ40 and Aβ42 in Alzheimer Disease
McNamara, M. J., Gomez-Isla, T., & Hyman, B. T. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.1001 · Cited by 55
Analysis of Association at Single Nucleotide Polymorphisms in the APOE Region
Martin, E. R., Gilbert, J. R., Lai, E., Riley, J., Rogala, A. R., Slotterbeck, B. D., Sipe, C. A., Grubber, J. M., Warren, L. L., Conneally, P. M., et al. (2000) · Genomics · doi:10.1006/geno.1999.6057 · Cited by 60
“The APOE4 allele has been shown to increase the risk for AD in a dose-related manner, while the APOE2 allele has been found to have a protective effect (Corder et al., 1994).”
BackgroundSelf-citationIn Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS
Wildsmith, K. R., Basak, J. M., Patterson, B. W., Pyatkivskyy, Y., Kim, J., Yarasheski, K. E., Wang, J. X., Mawuenyega, K. G., Jiang, H., Parsadanian, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038013 · Cited by 58
Baker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54
“ANOVA of pathology measures by apoE genotype demonstrated no significant relationships except for area fraction of -amyloid immunohistochemistry (10D5 antibody); F(3,42) 3.”
BackgroundCardenas, V. A., Reed, B., Chao, L. L., Chui, H. C., Sanossian, N., DeCarli, C. S., Mack, W. J., Kramer, J. H., Hodis, H. N., Yan, M., et al. (2012) · Stroke · doi:10.1161/strokeaha.112.659722 · Cited by 61
Salvadó, G., Grothe, M. J., Groot, C., Moscoso, A., Schöll, M., Gispert, J. D., Ossenkoppele, R., & Initiative, F. T. A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05192-8 · Cited by 52
Apolipoprotein E Genotype Regulates Amyloid-β Cytotoxicity
Wilhelmus, M. M. M., Otte-Höller, I., Davis, J., Van Nostrand, W. E., de Waal, R. M. W., & Verbeek, M. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4213-04.2005 · Cited by 53
“On the contrary, the 2 allele seems to have a protective effect against AD (Corder et al., 1994).”
Broderick, J. P., Lü, M., Jackson, C., Pancioli, A., Tilley, B. C., Fagan, S. C., Kothari, R., Levine, S. R., Marler, J. R., Lyden, P. D., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1058 · Cited by 57
Sciacca, B., François, A., Klingler‐Hoffmann, M., Brazzatti, J. A., Penno, M. A. S., Hoffmann, P., & Monro, T. M. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.10.007 · Cited by 58
“Comparing two different approaches for immobilizing the antibodies on the surface of the sensor, we demonstrate that the detection limit can be reduced if the antibodies are properly oriented, enabling efficient sensing and quantification of relevant concentration of human apoE, a relatively low-molecular-weight (~39…”
BackgroundInteractions of metals and Apolipoprotein E in Alzheimer’s disease
Xu, H. J., Finkelstein, D. I., & Adlard, P. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00121 · Cited by 66
“The least frequent APOE2 allele (found in 5–10% of individuals) seems to have a protective effect against the development of AD while the most frequent APOE3 allele (found in 70–80% of the population) represents intermediate risk (Corder et al., 1994; Mahley and Huang, 2006).”
BackgroundInferring Genome Ancestry and Estimating Molecular Relatedness Among 187 Chinese Maize Inbred Lines
Xie, C., Zhang, S., Li, M., Li, X., Hao, Z., Bai, L., Zhang, D., & Liang, Y. (2007) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/s1673-8527(07)60083-6 · Cited by 52
“man genetics, to detect QTL coding for simple and complex diseases [ 14 , 15], as well as in crops to detect”
BackgroundClinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease
Groot, C., Sudre, C. H., Barkhof, F., Teunissen, C. E., van Berckel, B. N. M., Seo, S. W., Ourselin, S., Scheltens, P., Cardoso, M. J., van der Flier, W. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006503 · Cited by 53
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.